Amarin Corp Plcuk (AMRN) Research & Development (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Research & Development of $4.8 million for Q2 2026, down 2.89% year-over-year from $4.9 million in Q2 2025, and up 2.32% quarter-over-quarter from $4.7 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Research & Development (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Research & Development for 17 consecutive years, with $4.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development fell 2.89% year-over-year to $4.8 million; the TTM figure through Jun 2026 stood at $19.0 million (down 8.36% YoY), while the FY2025 annual figure was $19.8 million, down 5.09% from the prior year.
- Research & Development grew to $4.8 million in Q2 2026 per AMRN's latest filing, from $4.7 million in the prior quarter.
- Across five years, Research & Development topped out at $10.1 million in Q1 2022 and bottomed at $4.2 million in Q3 2025.
- Historically, Research & Development has averaged $5.7 million across 5 years, with a median of $5.3 million in 2025.
- Annual changes were most pronounced in 2022 — Research & Development surged 47.18% — and 2023, when it tumbled 43.48%.
- Amarin Corp Plc\Uk's Research & Development stood at $5.2 million in 2022, then advanced by 10.54% to $5.8 million in 2023, then grew by 3.35% to $6.0 million in 2024, then fell by 10.26% to $5.4 million in 2025, then retreated by 11.13% to $4.8 million in 2026.
- Business Quant data shows AMRN's Research & Development at $4.8 million in Q2 2026, $4.7 million in Q1 2026, and $5.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Amarin Corp Plcuk | 5.88 Bn | 5.56 Bn | 14.99 Mn | 4.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.77 Mn |
| Mar 31, 2026 | 4.67 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Sep 30, 2025 | 4.21 Mn |
| Jun 30, 2025 | 4.92 Mn |
| Mar 31, 2025 | 5.31 Mn |
| Dec 31, 2024 | 5.99 Mn |
| Sep 30, 2024 | 4.54 Mn |
| Jun 30, 2024 | 4.75 Mn |
| Mar 31, 2024 | 5.60 Mn |
| Dec 31, 2023 | 5.79 Mn |
| Sep 30, 2023 | 5.11 Mn |
| Jun 30, 2023 | 5.64 Mn |
| Mar 31, 2023 | 5.68 Mn |
| Dec 31, 2022 | 5.24 Mn |
| Sep 30, 2022 | 5.77 Mn |
| Jun 30, 2022 | 9.36 Mn |
| Mar 31, 2022 | 10.05 Mn |
| Dec 31, 2021 | 5.75 Mn |
| Sep 30, 2021 | 7.82 Mn |